Abstract

More effective treatments are needed for low-grade serous ovarian carcinoma (LGSOC). Our patient, who suffers from metastatic LGSOC, had received all established treatments. Sequencing analysis revealed an activating BRAF mutation. Therefore, combined treatment with BRAF and MEK inhibitors, which is the gold standard in malignant melanoma, was initiated. After eight months of therapy, the response was assessed as complete and the treatment is still, 3.5 years after initiation, of benefit. To our knowledge, no complete response on combined BRAF and MEK inhibitor treatment of low-grade serous ovarian cancer has previously been reported.

摘要

低级别浆液性卵巢癌（LGSOC）需要更有效的治疗。我们的患者患有转移性 LGSOC，已接受所有既定治疗。测序分析显示存在激活的 BRAF 突变。因此，恶性黑色素瘤的金标准——BRAF和MEK抑制剂联合治疗应运而生。经过 8 个月的治疗后，疗效被评估为完全，并且在开始治疗 3.5 年后，治疗仍然有效。据我们所知，此前尚未报道过 BRAF 和 MEK 抑制剂联合治疗低级别浆液性卵巢癌完全缓解。